Header Logo

Connection

Jeremy Luban to Cell Line

This is a "connection" page, showing publications Jeremy Luban has written about Cell Line.
Connection Strength

1.587
  1. McCauley SM, Kim K, Nowosielska A, Dauphin A, Yurkovetskiy L, Diehl WE, Luban J. Intron-containing RNA from the HIV-1 provirus activates type I interferon and inflammatory cytokines. Nat Commun. 2018 12 13; 9(1):5305.
    View in: PubMed
    Score: 0.114
  2. Lascano J, Uchil PD, Mothes W, Luban J. TRIM5 Retroviral Restriction Activity Correlates with the Ability To Induce Innate Immune Signaling. J Virol. 2016 01 01; 90(1):308-16.
    View in: PubMed
    Score: 0.092
  3. Pizzato M, McCauley SM, Neagu MR, Pertel T, Firrito C, Ziglio S, Dauphin A, Zufferey M, Berthoux L, Luban J. Lv4 Is a Capsid-Specific Antiviral Activity in Human Blood Cells That Restricts Viruses of the SIVMAC/SIVSM/HIV-2 Lineage Prior to Integration. PLoS Pathog. 2015 Jul; 11(7):e1005050.
    View in: PubMed
    Score: 0.090
  4. Bartels H, Luban J. Gammaretroviral pol sequences act in cis to direct polysome loading and NXF1/NXT-dependent protein production by gag-encoded RNA. Retrovirology. 2014 Sep 12; 11:73.
    View in: PubMed
    Score: 0.085
  5. De Iaco A, Santoni F, Vannier A, Guipponi M, Antonarakis S, Luban J. TNPO3 protects HIV-1 replication from CPSF6-mediated capsid stabilization in the host cell cytoplasm. Retrovirology. 2013 Feb 15; 10:20.
    View in: PubMed
    Score: 0.076
  6. Pertel T, Hausmann S, Morger D, Z?ger S, Guerra J, Lascano J, Reinhard C, Santoni FA, Uchil PD, Chatel L, Bisiaux A, Albert ML, Strambio-De-Castillia C, Mothes W, Pizzato M, Gr?tter MG, Luban J. TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature. 2011 Apr 21; 472(7343):361-5.
    View in: PubMed
    Score: 0.067
  7. Santoni FA, Hartley O, Luban J. Deciphering the code for retroviral integration target site selection. PLoS Comput Biol. 2010 Nov 24; 6(11):e1001008.
    View in: PubMed
    Score: 0.066
  8. Sokolskaja E, Olivari S, Zufferey M, Strambio-De-Castillia C, Pizzato M, Luban J. Cyclosporine blocks incorporation of HIV-1 envelope glycoprotein into virions. J Virol. 2010 May; 84(9):4851-5.
    View in: PubMed
    Score: 0.062
  9. Neagu MR, Ziegler P, Pertel T, Strambio-De-Castillia C, Gr?tter C, Martinetti G, Mazzucchelli L, Gr?tter M, Manz MG, Luban J. Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. J Clin Invest. 2009 Oct; 119(10):3035-47.
    View in: PubMed
    Score: 0.060
  10. Sebastian S, Gr?tter C, Strambio de Castillia C, Pertel T, Olivari S, Gr?tter MG, Luban J. An invariant surface patch on the TRIM5alpha PRYSPRY domain is required for retroviral restriction but dispensable for capsid binding. J Virol. 2009 Apr; 83(7):3365-73.
    View in: PubMed
    Score: 0.058
  11. Berthoux L, Sebastian S, Muesing MA, Luban J. The role of lysine 186 in HIV-1 integrase multimerization. Virology. 2007 Jul 20; 364(1):227-36.
    View in: PubMed
    Score: 0.051
  12. Sokolskaja E, Berthoux L, Luban J. Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. J Virol. 2006 Mar; 80(6):2855-62.
    View in: PubMed
    Score: 0.047
  13. Sebastian S, Sokolskaja E, Luban J. Arsenic counteracts human immunodeficiency virus type 1 restriction by various TRIM5 orthologues in a cell type-dependent manner. J Virol. 2006 Feb; 80(4):2051-4.
    View in: PubMed
    Score: 0.047
  14. Berthoux L, Sebastian S, Sokolskaja E, Luban J. Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells. Proc Natl Acad Sci U S A. 2005 Oct 11; 102(41):14849-53.
    View in: PubMed
    Score: 0.046
  15. Gurer C, H?glund A, H?glund S, Luban J. ATPgammaS disrupts human immunodeficiency virus type 1 virion core integrity. J Virol. 2005 May; 79(9):5557-67.
    View in: PubMed
    Score: 0.045
  16. Gurer C, Berthoux L, Luban J. Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1. J Virol. 2005 Jan; 79(2):910-7.
    View in: PubMed
    Score: 0.044
  17. Sayah DM, Sokolskaja E, Berthoux L, Luban J. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature. 2004 Jul 29; 430(6999):569-73.
    View in: PubMed
    Score: 0.042
  18. Xue G, Yu HJ, Buffone C, Huang SW, Lee K, Goh SL, Gres AT, Guney MH, Sarafianos SG, Luban J, Diaz-Griffero F, KewalRamani VN. The HIV-1 capsid core is an opportunistic nuclear import receptor. Nat Commun. 2023 06 24; 14(1):3782.
    View in: PubMed
    Score: 0.039
  19. Berthoux L, Towers GJ, Gurer C, Salomoni P, Pandolfi PP, Luban J. As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity. J Virol. 2003 Mar; 77(5):3167-80.
    View in: PubMed
    Score: 0.038
  20. Gurer C, Cimarelli A, Luban J. Specific incorporation of heat shock protein 70 family members into primate lentiviral virions. J Virol. 2002 May; 76(9):4666-70.
    View in: PubMed
    Score: 0.036
  21. Colgan J, Asmal M, Luban J. Isolation, characterization and targeted disruption of mouse ppia: cyclophilin A is not essential for mammalian cell viability. Genomics. 2000 Sep 01; 68(2):167-78.
    View in: PubMed
    Score: 0.032
  22. Cimarelli A, Sandin S, H?glund S, Luban J. Basic residues in human immunodeficiency virus type 1 nucleocapsid promote virion assembly via interaction with RNA. J Virol. 2000 Apr; 74(7):3046-57.
    View in: PubMed
    Score: 0.031
  23. Burniston MT, Cimarelli A, Colgan J, Curtis SP, Luban J. Human immunodeficiency virus type 1 Gag polyprotein multimerization requires the nucleocapsid domain and RNA and is promoted by the capsid-dimer interface and the basic region of matrix protein. J Virol. 1999 Oct; 73(10):8527-40.
    View in: PubMed
    Score: 0.030
  24. Quitadamo B, Peters PJ, Repik A, O'Connell O, Mou Z, Koch M, Somasundaran M, Brody R, Luzuriaga K, Wallace A, Wang S, Lu S, McCauley S, Luban J, Duenas-Decamp M, Gonzalez-Perez MP, Clapham PR. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded. J Virol. 2018 01 15; 92(2).
    View in: PubMed
    Score: 0.027
  25. Braaten D, Ansari H, Luban J. The hydrophobic pocket of cyclophilin is the binding site for the human immunodeficiency virus type 1 Gag polyprotein. J Virol. 1997 Mar; 71(3):2107-13.
    View in: PubMed
    Score: 0.025
  26. Chen NY, Zhou L, Gane PJ, Opp S, Ball NJ, Nicastro G, Zufferey M, Buffone C, Luban J, Selwood D, Diaz-Griffero F, Taylor I, Fassati A. HIV-1 capsid is involved in post-nuclear entry steps. Retrovirology. 2016 Apr 23; 13:28.
    View in: PubMed
    Score: 0.024
  27. Rosa A, Chande A, Ziglio S, De Sanctis V, Bertorelli R, Goh SL, McCauley SM, Nowosielska A, Antonarakis SE, Luban J, Santoni FA, Pizzato M. HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation. Nature. 2015 Oct 08; 526(7572):212-7.
    View in: PubMed
    Score: 0.023
  28. Franke EK, Yuan HE, Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature. 1994 Nov 24; 372(6504):359-62.
    View in: PubMed
    Score: 0.022
  29. Luban J, Goff SP. Mutational analysis of cis-acting packaging signals in human immunodeficiency virus type 1 RNA. J Virol. 1994 Jun; 68(6):3784-93.
    View in: PubMed
    Score: 0.021
  30. Xu H, Franks T, Gibson G, Huber K, Rahm N, Strambio De Castillia C, Luban J, Aiken C, Watkins S, Sluis-Cremer N, Ambrose Z. Evidence for biphasic uncoating during HIV-1 infection from a novel imaging assay. Retrovirology. 2013 Jul 09; 10:70.
    View in: PubMed
    Score: 0.020
  31. Miyamoto T, Nakayama EE, Yokoyama M, Ibe S, Takehara S, Kono K, Yokomaku Y, Pizzato M, Luban J, Sugiura W, Sato H, Shioda T. The carboxyl-terminus of human immunodeficiency virus type 2 circulating recombinant form 01_AB capsid protein affects sensitivity to human TRIM5a. PLoS One. 2012; 7(10):e47757.
    View in: PubMed
    Score: 0.019
  32. Lai RP, Yan J, Heeney J, McClure MO, G?ttlinger H, Luban J, Pizzato M. Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41. PLoS Pathog. 2011 Dec; 7(12):e1002442.
    View in: PubMed
    Score: 0.018
  33. Kajaste-Rudnitski A, Marelli SS, Pultrone C, Pertel T, Uchil PD, Mechti N, Mothes W, Poli G, Luban J, Vicenzi E. TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements. J Virol. 2011 May; 85(10):5183-96.
    View in: PubMed
    Score: 0.017
  34. Singh R, Gaiha G, Werner L, McKim K, Mlisana K, Luban J, Walker BD, Karim SS, Brass AL, Ndung'u T. Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. J Virol. 2011 Jan; 85(1):208-16.
    View in: PubMed
    Score: 0.016
  35. O'Connor C, Pertel T, Gray S, Robia SL, Bakowska JC, Luban J, Campbell EM. p62/sequestosome-1 associates with and sustains the expression of retroviral restriction factor TRIM5alpha. J Virol. 2010 Jun; 84(12):5997-6006.
    View in: PubMed
    Score: 0.016
  36. Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog. 2009 Sep; 5(9):e1000574.
    View in: PubMed
    Score: 0.015
  37. Bernasconi R, Pertel T, Luban J, Molinari M. A dual task for the Xbp1-responsive OS-9 variants in the mammalian endoplasmic reticulum: inhibiting secretion of misfolded protein conformers and enhancing their disposal. J Biol Chem. 2008 Jun 13; 283(24):16446-54.
    View in: PubMed
    Score: 0.014
  38. Takeuchi H, Buckler-White A, Goila-Gaur R, Miyagi E, Khan MA, Opi S, Kao S, Sokolskaja E, Pertel T, Luban J, Strebel K. Vif counteracts a cyclophilin A-imposed inhibition of simian immunodeficiency viruses in human cells. J Virol. 2007 Aug; 81(15):8080-90.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.